"The U.S. Food and Drug Administration today approved a new use for Avastin (bevacizumab) to treat patients with persistent, recurrent or late-stage (metastatic) cervical cancer.
Cervical cancer grows in the tissues of the lower part of the "...
Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.
Noncontraceptive Health Benefits
The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral-contraceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.
Effects on menses
Â· Increased menstrual cycle regularity
Â· Decreased incidence of dysmenorrhea
Effects related to inhibition of ovulation:
Â· Decreased incidence of ectopic pregnancies
Effects from long-term use:
Â· Decreased incidence of fibroadenomas and fibrocystic disease of the breast
Â· Decreased incidence of acute pelvic inflammatory disease
Â· Decreased incidence of endometrial cancer
Â· Decreased incidence of ovarian cancer
Oral contraceptives should not be used in women with any of the following conditions:
This monograph has been modified to include the generic and brand name in many instances.
Â· Thrombophlebitis or thromboembolic disorders
Â· A past history of deep-vein thrombophlebitis or thromboembolic disorders
Â· Known or suspected carcinoma of the breast
Â· Hepatic adenomas or carcinomas
Â· Known or suspected pregnancy
Last reviewed on RxList: 5/16/2006
Additional Lutera Information
Lutera - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.